TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders~* Age ≥ 18 years old~* Give written informed consent to participate in the study after having been informed of the study design, objectives and possible derived risks~* Common mild to moderate dry eye symptoms. Persistent daily symptoms for more than three months:~* OSDI scale: 13-30~* VAS scale: 2-7~* Ocular tests in both eyes:~* Corneal staining with fluorescein. Oxford scale \> 0~* Tear Breakup Time Test: (BUT) \< 10 seconds~* Schirmer test with anaesthesia \< 10 mm/5min~Exclusion Criteria:~* Pregnant or breastfeeding females or those with a positive pregnancy test.~* Females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the whole study.~* Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal distress, hypertension, or infectious acute processes.~* Past history of a chronic o recurring condition that could interfere with study according to the investigator's judgement.~* Concomitant use of other drugs with analgesic activity by any route of administration at the enrolment period.~* Changes in any ocular and/or systemic concomitant medication one month prior to the study commencement and during the study development.~* Changes on the preestablished artificial tears dosage 15 days prior to the study commencement and during the study development.~* Cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen during the 6 months prior to enrolment.~* Previous history of drug hypersensitivity.~* Use of contact lenses~* Case history of drug or alcohol abuse or dependence.~* Relevant abnormal laboratory results as judged by the investigator~* Previous refractive surgery~* Participation in a clinical trial within 2 months before the enrolment visit~* Relevant ocular pathology judged by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYL1001 eye drops dose A (Type: EXPERIMENTAL): Ocular topical administration of SYL1001 eye drops dose A
- Placebo (Type: PLACEBO_COMPARATOR): Ocular topical administration of placebo eye drops

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* advanced (stage IIIB/IV)non-small cell lung cancer;~* measurable disease;~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1.~Exclusion Criteria:~* prior exposure to agents directed at the HER axis;~* prior chemotherapy or systemic anti-tumor therapy after advanced disease;~* unstable systemic disease;~* any other malignancy within last 5 years, except cured basal cell cancer of skin or cured cancer in situ of cervix;~* brain metastasis or spinal cord compression.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rheumatoid arthritis~* Eligible for biologic therapy according to BSR/NICE guidelines~Exclusion Criteria:~* Prior biologic therapy~* Contra-indication to anti-TNF therapy or rituximab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anti-TNF therapy (Type: ACTIVE_COMPARATOR): Etanercept or adalimumab by s/c injection
- Rituximab therapy (Type: EXPERIMENTAL): Rituximab given by IV infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sexual Function and Wellbeing in Males With Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males diagnosed with rectal cancer stadium I-III, planned for surgery with or without preoperative radiotherapy or males with prostate cancer stadium I-III planned for robot-assisted prostatectomy without preoperative radiotherapy.~* Informed consent~* Fluent in Swedish~* Residents of the Stockholm county area~Exclusion Criteria:~* Rectal cancer stadium IV~* Previous radiotherapy to the pelvic region~* History or evidence of a second pelvic malignancy~* Androgen deprivation therapy, Testosterone replacement or Androgen abuse

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preoperative RT (Type: None): Men with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
- No preoperative RT (Type: None): Men with rectal cancer or prostate cancer treated with surgery alone (no RT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients will be eligible for inclusion if they meet all of the below criteria. Criteria 1-3 must all be present within a 24-hour time period and at the time of enrollment:~Acute onset (defined below) of:~1. A need for positive pressure ventilation by an endotracheal or tracheal tube with a PaO2/FiO2 ratio \< 200 with at least 8 cm H2O positive end-expiratory airway pressure (PEEP)~2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph~3. No clinical evidence of left atrial hypertension for bilateral pulmonary infiltrates.~In addition to meeting inclusion criteria, enrollment must occur within 96-hours of first meeting ARDS criteria per the Berlin definition of ARDS.~Exclusion Criteria:~1. Age less than 18 years~2. Greater than 96 hours since first meeting ARDS criteria per the Berlin definition of ARDS~3. Pregnant or breast-feeding~4. Prisoner~5. Presence of any active malignancy (other than non-melanoma skin cancer) that required treatment within the last 2 years~6. Any other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%~7. Moderate to severe liver failure (Childs-Pugh Score \> 12)~8. Severe chronic respiratory disease with a PaCO2 \> 50 mm Hg or the use of home oxygen~9. Patient, surrogate, or physician not committed to full support (exception: a patient will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest).~10. Major trauma in the prior 5 days~11. Lung transplant patient~12. No consent/inability to obtain consent~13. Moribund patient not expected to survive 24 hours~14. WHO Class III or IV pulmonary hypertension~15. Documented deep venous thrombosis or pulmonary embolism within past 3 months~16. No arterial line/no intent to place an arterial line~17. No intent/unwillingness to follow lung protective ventilation strategy or fluid management protocol~18. Currently receiving extracorporeal life support (ECLS) or high-frequency oscillatory ventilation (HFOV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (Type: EXPERIMENTAL): A dose-escalation with 3 cohorts with 3 subjects/cohort who receive doses of 1, 5 and 10 million cells/kg predicted body weight (PBW). Proceed from lower dose to next higher dose if no safety concerns for each cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnostic criteria for MDD (diagnosed with the use of SCID)~* Written informed consent~* Men or women aged 18-65~* A baseline Hamilton-D17 score of \> 16.~Exclusion Criteria:~* Subjects with suicidal ideation where outpatient treatment is determined unsafe by the study clinician. These patients will be immediately referred to appropriate clinical treatment.~* Pregnant women or women of childbearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)~* Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease~* History of seizure disorder,~* History or current diagnosis of the following DSM-IV psychiatric illness: organic mental disorder, schizophrenia, schizoaffective disorder, delusional disorder, psychotic disorders not otherwise specified, bipolar disorder, patients with mood congruent or mood incongruent psychotic features, patients with substance dependence disorders, including alcohol, active within the last 12 months.~* History or current diagnosis of dementia, or a score of \< 26 on the Mini Mental Status Examination (Folstein, 1975) at the screening visit.~* History of multiple adverse drug reactions or allergy to the study drugs.~* Patients with mood congruent or mood incongruent psychotic features.~* Patients having shown minimal or no response to a standard course of antidepressant treatment with an SSRI. A standard course will be defined as the following medications taken for \> 4 weeks: fluoxetine \> 20 mg/day, sertraline \> 50 mg/day, paroxetine \> 20 mg/day, fluvoxamine \> 50 mg/day, citalopram \> 20 mg/day, venlafaxine \> 150 mg/day.~* Clinical or laboratory evidence of hypothyroidism.~* Patients who have had electroconvulsive therapy (ECT) within the 6 months preceding baseline.~* History of intolerance to Cytomel~* History of cardiac pathology or diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with mucosal leishmaniasis confirmed by a positive smear, in vitro culture or PCR test~Exclusion Criteria:~* Mucosal leishmaniasis must not involve the vocal cords or cause respiratory distress, and there must be no evidence of other disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy men and women, age 40-75 yrs, without any disease and need of medication.~* Born, raised and currently living at low altitude (\<800m).~* Written informed consent.~* Kyrgyz ethnicity~Exclusion Criteria:~* Any active respiratory, cardiovascular or other disease requiring regular treatment or being otherwise relevant for tolerance of hypoxia or altitude exposure.~* Any condition that may interfere with protocol compliance including current heavy smoking (\>20 cigarettes per day or \>20 pack-years with active smoking during the last 10 years), regular use of alcohol.~* Allergy to acetazolamide and other sulfonamides.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- ACETAZOLAMIDE oral capsule (Type: ACTIVE_COMPARATOR): Acetazolamide 375mg/day (capsule @125 mg: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m
- PLACEBO oral capsule (Type: PLACEBO_COMPARATOR): Placebo (capsules identically looking as acetazolamide capsules: 1 in the morning, 2 in the evening), orally. Medication starts 24 hours before ascent to 3'100m until the morning after the second night at 3'100m.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Status and Hypoxic Pulmonary Vascular Responses

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give informed consent for participation in the study~* Men and women aged 18 years or older and generally in good health~* Detectable tricuspid regurgitation on echocardiography during both normoxia and hypoxia enabling measurement of pulmonary arterial pressure~* For iron-deficient volunteers: ferritin ≤15microg/L and transferrin saturation \<16%~* For iron-replete volunteers: ferritin ≥20microg/L and transferrin saturation ≥20%~Exclusion Criteria:~* Haemoglobin \<8.0g/dl~* Haemoglobinopathy~* Iron overload defined as ferritin \>300microg/L~* Hypoxia at rest or on walking (SaO2 \<94%) or significant comorbidity that may affect haematinics, pulmonary vascular or ventilatory responses, e.g. current infection, a chronic inflammatory condition, known cardiovalvular lesion or pulmonary hypertension, uncontrolled asthma or chronic obstructive pulmonary disease~* Exposure to high altitude (\>2,500m) within the previous six weeks or air travel \>4 hours within the previous week~* Iron supplementation or blood transfusion within the previous 6 weeks~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Iron-deficient (Type: OTHER): Healthy volunteers meeting iron-deficient entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures
- Iron-replete (Type: OTHER): Healthy volunteers meeting iron-replete entry criteria; Intravenous administration of ferric carboxymaltose; Subacute hypoxic exposures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of plaque-type psoriasis for at least 6 months~* Patients with plaque-type psoriasis covering at least 10% of the body~Exclusion Criteria:~* Patients with nonplaque forms of psoriasis~* Patients who have current drug-induced psoriasis~* Patients who are pregnant, nursing, or planning pregnancy (both men and women) within 18 months of enrollment~* Patients who had any previous treatment with infliximab or any therapeutic agent targeted at reducing tumor necrosis factor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 19 to 75 years~2. Patients diagnosed with ASCVD (coronary artery disease)~   * acute coronary syndrome~  * history of myocardial infarction (MI)~  * stable or unstable angina~  * history of coronary revascularization~  * stroke or transient ischemic attack (TIA)~  * peripheral arterial disease, history of peripheral arterial revascularization~3. Taking a stable dose of a statin or a lipid-lowering agent of ezetimibe over 4 weeks before randomization~4. Written informed consent~Exclusion Criteria:~1. Administration of other lipid lowering agents than statin or ezetimibe within 3 months prior to screening visit~2. Fasting triglyceride ≥ 400 mg/dL~3. History of muscular disease or rhabdomyolysis due to use of statin~4. Hypersensitive to rosuvastatin or ezetemibe~5. Contraindications stated in the SPC of rosuvastatin or rosuvastatin/ezetimibe including the following:~   ① Severe renal disease (CrCL \< 30mL/min: Cockcroft-gault formula or estimated GFR (MDRD) \< 30mL/min/1.73m2)~   ② ALT, AST \> 3x ULN or history of active liver disease~   ③ CPK \> 3x ULN~6. Administration of other investigational products within 30 days prior to screening visit~7. Other than the above who is deemed to be ineligible to participate in the trial by investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Rosuvamibe Tab (Type: EXPERIMENTAL): Rosuvastatin 10mg/Ezetimibe 10mg qd for 24 weeks
- Monorova Tab (Type: ACTIVE_COMPARATOR): Rosuvastatin 20mg qd for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protocol for Women at Increased Risk of Developing Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast~* on hormone replacement therapy~* postmenopausal~* increased risk of developing breast cancer based on personal or family history~* never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months~* women who have a high risk of breast cancer~* older than 18 years~Exclusion Criteria:~* anticoagulants~* marked breast tenderness~* pregnant or within twelve months of breast feeding/childbirth

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral Letrozole 2.5 mg daily for six months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Effects of Iron Levels on the Lungs at High Altitude

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
SLR ARM~Inclusion Criteria:~* sea level natives of lowland ancestry~* generally in good health~* detectable tricuspid regurgitation on echocardiography~Exclusion Criteria:~* any significant medical problem~* known susceptibility to high altitude pulmonary or cerebral oedema~* taking medications or iron supplements~CMS ARM~Inclusion Criteria:~* diagnosis of chronic mountain sickness~* no recent venesection therapy (within 1 year)~* detectable tricuspid regurgitation on echocardiography~Exclusion Criteria:~* any other significant medical problem

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CMS - placebo first (Type: PLACEBO_COMPARATOR): Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive a placebo (saline) infusion first followed by iron infusion.
- CMS - iron (Type: EXPERIMENTAL): Patients with chronic mountain sickness (CMS) who are venesected and studied for several weeks. In the final crossover period of the study, patients receive an iron infusion first followed by placebo (saline) infusion.
- SLR - placebo (Type: PLACEBO_COMPARATOR): Sea level residents (SLR) taken to high altitude for one week, and receiving placebo (saline) infusion on Day 3 at high altitude.
- SLR - iron (Type: EXPERIMENTAL): Sea level residents (SLR) taken to high altitude for one week, and receiving iron infusion on Day 3 at high altitude.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete